Drug Trial Radar · NCT06204809
Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1
Last checked: Nov 20, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Dec 12, 2023
Primary completion
Oct 28, 2025
Study completion Oct 28, 2025
Sponsor
- Lead sponsor
- PepGen IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) doses of PGN-EDODM1 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 2 periods: A Screening Period (up to 30 days) and a Treatment and Observation Period (16 weeks).
Conditions
- Myotonic Dystrophy 1
Interventions
PGN-EDODM1 for infusionDrug
Single dose of PGN-EDODM1 by intravenous (IV) infusion
PlaceboOther
Administered by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events, Serious Adverse Events, with abnormal Clinical Laboratory tests, abnormal ECGs, and abnormal Vital SignsTime frame: Baseline to Week 16
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
UCI Center for Clinical Research
Irvine, California
Stanford University
Palo Alto, California
Rare Disease Research
Atlanta, Georgia
University of Kansas Medical Center
Fairway, Kansas
Massachusetts General Hospital
Boston, Massachusetts
University of Rochester Medical Center
Rochester, New York
Virginia Commonwealth University
Richmond, Virginia
University of Calgary
Calgary, Alberta, Canada
Ottawa Hospital Research Institute (OHRI)
Ottawa, Ontario, Canada
CIUSSS du Saguenay-Lac-Saint-Jean
Chicoutimi, Quebec, Canada
Salford Royal Hospital
Salford, United Kingdom
University College London Hospital
London, UK, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.